Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.
Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.
Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.
Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.
Unfavorable Teva risk/reward and steep valuation keeps Oppenheimer on the sidelines.
From right and left, analysts to credit agencies are downgrading or cutting expectations on TEVA; here’s why.
Goldman Sachs: Cost cutting could be what TEVA needs to find stable ground once again.
Jason Kolbert: Rising generics rivalry coupled with price erosion do not bode positively for TEVA.
Louise Chen is dialing down the price target on TEVA after a rocky third quarter performance.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced it has completed the sale of Plan B …